We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-4.00 | -0.03% | 12,100.00 | 12,084.00 | 12,088.00 | 12,096.00 | 11,990.00 | 12,020.00 | 923,841 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.46 | 187.63B |
By Colin Kellaher
American depositary share of Gracell Biotechnologies surged nearly 60% in premarket trading Tuesday after the clinical-stage biopharmaceutical company agreed to be acquired by pharmaceutical giant AstraZeneca in a deal worth up to $1.2 billion.
AstraZeneca is paying an initial $1 billion, or $10 an ADS, in cash for Gracell, a nearly 62% premium to Friday's closing price of $6.19 for the Shanghai-based company.
Gracell said its investors also will receive non-tradable contingent value rights tied to a future regulatory milestone that are worth up to $1.50 an ADS in cash, bringing the total potential deal value to $11.50 an ADS, about 86% above Friday's closing price.
Gracell ADSs were recently up 58% to $9.76 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 26, 2023 06:29 ET (11:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions